146 related articles for article (PubMed ID: 12271154)
1. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
Hasinoff BB
Cardiovasc Toxicol; 2002; 2(2):111-8. PubMed ID: 12271154
[TBL] [Abstract][Full Text] [Related]
2. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
3. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria.
Hasinoff BB; Schnabl KL; Marusak RA; Patel D; Huebner E
Cardiovasc Toxicol; 2003; 3(2):89-99. PubMed ID: 14501028
[TBL] [Abstract][Full Text] [Related]
4. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
Barnabé N; Zastre JA; Venkataram S; Hasinoff BB
Free Radic Biol Med; 2002 Jul; 33(2):266-75. PubMed ID: 12106822
[TBL] [Abstract][Full Text] [Related]
5. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D
J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
[TBL] [Abstract][Full Text] [Related]
6. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Schroeder PE; Hasinoff BB
Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
Schroeder PE; Hasinoff BB
Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
[TBL] [Abstract][Full Text] [Related]
8. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D; Wu X
Free Radic Biol Med; 2003 Dec; 35(11):1469-79. PubMed ID: 14642395
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
Malisza KL; Hasinoff BB
Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
Schroeder PE; Wang GQ; Burczynski FJ; Hasinoff BB
Drug Metab Dispos; 2005 Jun; 33(6):719-25. PubMed ID: 15764716
[TBL] [Abstract][Full Text] [Related]
11. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
12. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane).
Hasinoff BB
Free Radic Res; 1995 Apr; 22(4):319-25. PubMed ID: 7633562
[TBL] [Abstract][Full Text] [Related]
13. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
Vaidyanathan S; Boroujerdi M
Cancer Chemother Pharmacol; 2000; 46(2):93-100. PubMed ID: 10972478
[TBL] [Abstract][Full Text] [Related]
14. A QSAR study that compares the ability of bisdioxopiperazine analogs of the doxorubicin cardioprotective agent dexrazoxane (ICRF-187) to protect myocytes with DNA topoisomerase II inhibition.
Hasinoff BB; Patel D; Wu X
Toxicol Appl Pharmacol; 2020 Jul; 399():115038. PubMed ID: 32417440
[TBL] [Abstract][Full Text] [Related]
15. The doxorubicin cardioprotective agent dexrazoxane (ICRF-187) induces endopolyploidy in rat neonatal myocytes through inhibition of DNA topoisomerase II.
Hasinoff BB; Takeda K; Ferrans VJ; Yu ZX
Anticancer Drugs; 2002 Mar; 13(3):255-8. PubMed ID: 11984069
[TBL] [Abstract][Full Text] [Related]
16. Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.
Spagnuolo RD; Recalcati S; Tacchini L; Cairo G
Br J Pharmacol; 2011 May; 163(2):299-312. PubMed ID: 21232037
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
18. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
[TBL] [Abstract][Full Text] [Related]
19. Chemistry of dexrazoxane and analogues.
Hasinoff BB
Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]